Journal of Carcinogenesis & Mutagenesis

Advances in Understanding Drug Resistance in Carcinogenesis

Ridhi Deng^* Department of Life Technologies, University of Turku, Turku, Finland
^*Correspondence: Ridhi Deng, Department of Life Technologies, University of Turku, Turku, Finland, Tel: ridhi@deng123245.fi,

Received: 31-Dec-2026, Manuscript No. JCM-26-31150 ; Editor assigned: 02-Jan-2026, Pre QC No. JCM-26-31150 (PQ); Reviewed: 16-Jan-2026, QC No. JCM-26-31150; Revised: 23-Jan-2026, Manuscript No. JCM-26-31150 (R); Published: 30-Jan-2026, DOI: 10.35248/2157-2518.26.17.496

Description

Drug resistance remains one of the most formidable challenges in modern oncology, significantly limiting the effectiveness of anticancer therapies and contributing to disease recurrence and mortality. It refers to the ability of cancer cells to withstand the cytotoxic effects of drugs that were initially effective. This phenomenon can be broadly categorized into intrinsic resistance, where tumor cells are inherently unresponsive to treatment, and acquired resistance, which develops after initial exposure to therapeutic agents. Understanding the biological and molecular basis of drug resistance is critical for improving treatment outcomes and advancing precision medicine.

Multiple mechanisms contribute to the development of drug resistance in cancer cells. One of the well-characterized mechanisms involves alterations in drug transport. Cancer cells can reduce intracellular drug accumulation by decreasing drug uptake or increasing drug efflux through membrane transporters such as ATP-binding cassette proteins. This leads to sub therapeutic intracellular drug concentrations, thereby reducing drug efficacy. Additionally, enhanced drug metabolism can inactivate chemotherapeutic agents before they exert their cytotoxic effects.

Genetic and epigenetic changes also play a crucial role in drug resistance. Mutations in drug targets can alter the binding affinity of therapeutic agents, rendering them ineffective. For instance, mutations in kinases targeted by small molecule inhibitors can prevent drug binding, leading to therapeutic failure. Epigenetic modifications such as DNA methylation and histone modification can regulate gene expression without altering the DNA sequence, thereby influencing drug sensitivity. These changes can activate survival pathways or silence genes involved in apoptosis, enabling cancer cells to evade druginduced cell death.

Another significant mechanism involves the activation of alternative signaling pathways. Cancer cells can bypass inhibited pathways by activating compensatory signaling networks, thereby maintaining proliferation and survival. This redundancy in signaling pathways underscores the complexity of cancer biology and highlights the limitations of single-agent therapies. Tumor heterogeneity further exacerbates this issue, as different subpopulations of cells within the same tumor may respond differently to treatment, allowing resistant clones to expand under selective pressure.

The tumor microenvironment also contributes to drug resistance. Interactions between cancer cells and surrounding stromal cells, immune cells, and extracellular matrix components can create a protective niche that promotes survival and resistance. Hypoxic conditions within tumors can induce adaptive responses that reduce drug sensitivity, including the activation of hypoxia-inducible factors and metabolic reprogramming. Moreover, the presence of cancer stem cells, a subpopulation with self-renewal capabilities, has been implicated in resistance due to their inherent ability to withstand conventional therapies.

Efforts to overcome drug resistance have led to the development of various strategies. Combination therapy, which involves the use of multiple drugs targeting different pathways, aims to prevent the emergence of resistant clones and enhance therapeutic efficacy. Targeted therapies and immunotherapies have shown promise in overcoming resistance by specifically attacking molecular abnormalities or enhancing the immune response against cancer cells. Additionally, the identification of predictive biomarkers can help tailor treatments to individual patients, improving response rates and minimizing unnecessary toxicity.

In conclusion, drug resistance continues to represent a critical barrier in the successful treatment of cancer, driven by a complex interplay of molecular, cellular, and environmental factors. Although substantial progress has been made in understanding its underlying mechanisms, overcoming resistance requires integrated therapeutic approaches, continued research, and the development of personalized treatment strategies. Addressing drug resistance effectively is essential for improving long-term clinical outcomes and achieving durable remission in cancer patients.